Rapport Therapeutics Reports Positive Topline Results in Phase 2 Bipolar Mania Trial
Rapport Therapeutics announced statistically significant improvements in patients with bipolar mania treated with its drug RAP-219, marking a key milestone toward potential Phase 3 trials and establishing clinical proof-of-concept.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed